• +1-646-491-9876
    • +91-20-67278686

    Search

    Aspergillosis Pipeline Review H1 2017

    Aspergillosis Pipeline Review H1 2017

    • Report Code ID: RW0001799298
    • Category Pharmaceuticals
    • No. of Pages 101
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Aspergillosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

    Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise) , weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

    Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Aspergillosis - Overview
    Aspergillosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Aspergillosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Aspergillosis - Companies Involved in Therapeutics Development
    Amplyx Pharmaceuticals Inc
    Astellas Pharma Inc
    Biomar Microbial Technologies
    Biosergen AS
    Cidara Therapeutics Inc
    F2G Ltd
    Hsiri Therapeutics LLC
    iCo Therapeutics Inc.
    Matinas BioPharma Holdings Inc
    Merck & Co Inc
    Nanomerics Ltd
    Novabiotics Ltd
    Pulmatrix Inc
    Pulmocide Ltd
    Scynexis Inc
    Sealife PHARMA GMBH
    Sigma-Tau SpA
    Vical Inc
    Visterra Inc
    Aspergillosis - Drug Profiles
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amphotericin B - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Amphotericin B sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APX-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APX-001A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-9726 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspergillus fumigatus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BSG-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CD-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    celastrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    F-901318 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    itraconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KB-425796C - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MDN-0018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NP-339 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PC-945 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    posaconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PTX-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCY-078 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SLP-0901 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SLP-0904 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Aspergillosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Aspergillosis and Candidiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Fungal Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Fungal Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Invasive Aspergillosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIS-FNG - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VL-2397 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspergillosis - Dormant Projects
    Aspergillosis - Discontinued Products
    Aspergillosis - Product Development Milestones
    Featured News & Press Releases
    May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
    Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
    Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings
    Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318
    Dec 13, 2016: SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
    Nov 28, 2016: Cidara Therapeutics' Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
    Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
    Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS
    Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
    Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
    Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH
    Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
    May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
    Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
    Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Aspergillosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
    Aspergillosis - Pipeline by Astellas Pharma Inc, H1 2017
    Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2017
    Aspergillosis - Pipeline by Biosergen AS, H1 2017
    Aspergillosis - Pipeline by Cidara Therapeutics Inc, H1 2017
    Aspergillosis - Pipeline by F2G Ltd, H1 2017
    Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H1 2017
    Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2017
    Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Aspergillosis - Pipeline by Merck & Co Inc, H1 2017
    Aspergillosis - Pipeline by Nanomerics Ltd, H1 2017
    Aspergillosis - Pipeline by Novabiotics Ltd, H1 2017
    Aspergillosis - Pipeline by Pulmatrix Inc, H1 2017
    Aspergillosis - Pipeline by Pulmocide Ltd, H1 2017
    Aspergillosis - Pipeline by Scynexis Inc, H1 2017
    Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2017
    Aspergillosis - Pipeline by Sigma-Tau SpA, H1 2017
    Aspergillosis - Pipeline by Vical Inc, H1 2017
    Aspergillosis - Pipeline by Visterra Inc, H1 2017
    Aspergillosis - Dormant Projects, H1 2017
    Aspergillosis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Aspergillosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amplyx Pharmaceuticals Inc
    Astellas Pharma Inc
    Biomar Microbial Technologies
    Biosergen AS
    Cidara Therapeutics Inc
    F2G Ltd
    Hsiri Therapeutics LLC
    iCo Therapeutics Inc.
    Matinas BioPharma Holdings Inc
    Merck & Co Inc
    Nanomerics Ltd
    Novabiotics Ltd
    Pulmatrix Inc
    Pulmocide Ltd
    Scynexis Inc
    Sealife PHARMA GMBH
    Sigma-Tau SpA
    Vical Inc
    Visterra Inc

    Request for Sample

    Report Url http://www.reportsweb.com//aspergillosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//aspergillosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//aspergillosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments